Transmeta Corporation (NASDAQ:TMTA) today reports that NEC Electronics’
recently announced M2 Mobile Phone Chip uses Transmeta’s
LongRun2 technologies. The M2 is fabricated in NEC Electronics’
advanced 65-nanometer process technology and incorporates LongRun2
technologies to help manage threshold voltage and leakage current. NEC
Electronics became Transmeta’s first LongRun2
licensee in March 2004 and its M2 Mobile Phone Chip is the first
licensed commercial product to implement Transmeta’s
LongRun2 technologies.
"Transmeta congratulates NEC Electronics on
its M2 product announcement. We are proud that NEC Electronics has
incorporated LongRun2 technologies as one key element of the low power
capabilities of their 65nm process technology,”
said Les Crudele, president and chief executive officer of Transmeta. "This
is an important milestone and demonstrates the value that LongRun2
technologies provide to our customers.” About Transmeta Corporation
Transmeta Corporation develops and licenses innovative computing,
microprocessor and semiconductor technologies and related intellectual
property. Founded in 1995, we first became known for designing,
developing and selling our highly efficient x86-compatible
software-based microprocessors, which deliver a balance of low power
consumption, high performance, low cost and small size suited for
diverse computing platforms. We are presently focused on developing and
licensing our advanced power management technologies for controlling
leakage and increasing power efficiency in semiconductor and computing
devices, and in licensing our computing and microprocessor technologies
to other companies. To learn more about Transmeta, visit www.transmeta.com.
Safe Harbor Statement
This release contains forward-looking statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such statements speak only as of the date of this release, and
we will not necessarily provide updates of our projections or other
forward-looking statements. Investors are cautioned that such
forward-looking statements are subject to many risks and uncertainties,
and may differ materially or adversely from our actual results or future
events. Important risk factors that could have material or adverse
effects on our results include practical difficulties in implementing
our restructuring plan and modifying our business model, the potential
loss of key technical and business personnel, our ability to satisfy the
continued listing requirements of the
Nasdaq Stock Market, uncertainty
about the adoption and market acceptance of our technology offerings by
current and potential customers and licensees, our inability to predict
or ensure that third parties will license our technologies or use our
technologies to generate royalties, difficulties in developing our
technologies in a timely and cost effective manner, the risk that we
have difficulties entering into strategic collaborations or raising
financing on satisfactory terms, patents and other intellectual property
rights, and other risk factors. We urge investors to review our filings
with the Securities and Exchange Commission, including our most recent
reports on Forms 10-Q, 10-K and 8-K, which describe these and other
important risk factors that could have an adverse effect on our results.
We undertake no obligation to revise or update publicly any
forward-looking statement for any reason.
Transmeta and LongRun2 are trademarks of Transmeta Corporation. All
other product or service names mentioned herein are the trademarks of
their respective owners.
